IDEXX Laboratories, Inc. vs T-Mobile Us Inc — how do they compare? IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B), while T-Mobile Us Inc trades at $148.45 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 4.5× IDEXX Laboratories, Inc.'s market cap, and T-Mobile Us Inc pays a 2.73% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and T-Mobile Us Inc for 84 Days on average.
| IDXX | TMUS | |
|---|---|---|
Market Cap | $40.43B | $183.76B |
Volume | 692,164 | 4,294,650 |
Sector | Health | Media |
52-Week High | $766.68 | $230.06 |
52-Week Low | $504.70 | $161.73 |
Typical Hold Time | 46 Days | 84 Days |
Enterprise Value | $41.32B | $300.37B |
Dividend Yield | — | 2.73% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
T-Mobile (TMUS) is trading at $149.79, down 10.64% in the last session. The stock shows strong fundamentals with revenue growth from $81.4B in 2024 to $88.3B in 2025 and robust profitability (net margin 11.45%). Recent technical indicators are mixed with a bearish moving average signal but neutral oscillators. The company announced a 15% dividend increase and is advancing AI-powered 5G network capabilities. Analyst consensus remains strongly bullish with 79.6% buy ratings and a $231.10 price target.
TMUS presents a compelling growth story with solid financials and strategic initiatives, though elevated debt levels and competitive pressures pose risks. The current price decline may offer an entry point given the significant upside to analyst targets, supported by consistent earnings beats and dividend growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →